Recent Security Class Actions

Myriad Genetics Inc. Common Stock (NASDAQ: MYGN)

Company Name:Myriad Genetics Inc. Common Stock
Stock Symbol:NASDAQ: MYGN
Class Period Start:08/09/2017
Class Period End (inclusive):02/06/2020
Filing Deadline:11/26/2019

According to the Complaint, Myriad is a molecular diagnostic company that develops and markets predictive, personalized, and prognostic medicine tests worldwide. Myriad offers, among other products, GeneSight, a DNA genotyping test to aid psychotropic drug selection for depressed patients; and Foresight, a prenatal test in the expanded carrier screening market for future parents to assess their risk of passing on a recessive genetic condition to their offspring.